Developing a new treatment for idiopathic pulmonary fibrosis
Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis
This study is looking at a new treatment called M10 that might help people with idiopathic pulmonary fibrosis (IPF) by reducing the harmful changes in their lung cells, with the hope of being more effective and having fewer side effects than current options.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fibrobiologics, LLC NIH-funded |
| Lab location | 1 site (Charleston, United States) |
| Project ID | NIH-10696538 on NIH RePORTER |
What this research studies
This research focuses on creating a novel peptide therapeutic agent aimed at treating idiopathic pulmonary fibrosis (IPF), a serious lung disease. The approach involves testing the effectiveness of a peptide called M10 in inhibiting the fibrotic processes in lung cells taken from IPF patients. By leveraging advancements in peptide formulation, the study aims to develop a treatment that is both effective and has fewer side effects compared to existing medications. The research will assess how well M10 can reduce the harmful characteristics of lung fibroblasts associated with IPF.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis who are seeking new treatment options.
Not a fit: Patients with other forms of lung disease or those who do not have idiopathic pulmonary fibrosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a more effective and less toxic treatment option for patients suffering from idiopathic pulmonary fibrosis.
How similar studies have performed: While there have been advancements in peptide therapies, this specific approach targeting idiopathic pulmonary fibrosis is relatively novel and has not been extensively tested.
Where this research is happening
Charleston, United States
- Fibrobiologics, LLC — Charleston, United States (Active)
Researchers
- Principal investigator: Bogatkevich, Galina S — Fibrobiologics, LLC
- Study coordinator: Bogatkevich, Galina S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.